CareDx Inc  

(Public, NASDAQ:CDNA)   Watch this stock  
Find more results for J. Fred Miller, III
4.97
+0.30 (6.42%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.60 - 5.00
52 week 3.70 - 7.49
Open 4.60
Vol / Avg. 0.00/22,449.00
Mkt cap 70.44M
P/E     -
Div/yield     -
EPS -1.78
Shares 13.96M
Beta     -
Inst. own 45%
Aug 8, 2016
Q2 2016 CareDx Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
CareDx Inc at Jefferies Healthcare Conference
May 6, 2016
Q1 2016 CareDx Inc Earnings Release
May 6, 2016
Q1 2016 CareDx Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -148.61% -48.70%
Operating margin -100.11% -42.40%
EBITD margin - -39.57%
Return on average assets -74.88% -23.48%
Return on average equity -156.60% -38.72%
Employees 55 -
CDP Score - -

Address

3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States - Map
+1-415-2872300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Officers and directors

Michael D. Goldberg Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Peter Maag Ph.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Charles Constanti Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Mitchell J. Nelles Ph.D. Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
John J. Sninsky Ph.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Josh DeFonzo Chief Commercial Officer
Age: 34
Bio & Compensation  - Reuters
Matthew J. Meyer Chief Business Officer
Age: 46
Bio & Compensation  - Reuters
James P. Yee M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Douglas S. Miller Director
Age: 58
Bio & Compensation  - Reuters
George W. Bickerstaff III Independent Director
Age: 60
Bio & Compensation  - Reuters